Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global... von Camidge, D. Ross, Dziadziuszko, Rafal, Peters, Solange, Mok, Tony, Noe, Johannes, Nowicka, Malgorzata, Gadgeel, Shirish M., Cheema, Parneet, Pavlakis, Nick, de Marinis, Filippo, Cho, Byoung Chul, Zhang, Li, Moro-Sibilot, Denis, Liu, Ting, Bordogna, Walter, Balas, Bogdana, Müller, Barbara, Shaw, Alice T.

Volltext

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial von Rittmeyer, Achim, MD, Barlesi, Fabrice, PhD, Waterkamp, Daniel, MD, Park, Keunchil, MD, Ciardiello, Fortunato, MD, von Pawel, Joachim, MD, Gadgeel, Shirish M, MD, Hida, Toyoaki, PhD, Kowalski, Dariusz M, PhD, Dols, Manuel Cobo, MD, Cortinovis, Diego L, PhD, Leach, Joseph, MD, Polikoff, Jonathan, MD, Barrios, Carlos, MD, Kabbinavar, Fairooz, MD, Frontera, Osvaldo Arén, MD, De Marinis, Filippo, MD, Turna, Hande, MD, Lee, Jong-Seok, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, He, Pei, PhD, Chen, Daniel S, MD, Sandler, Alan, MD, Gandara, David R, Dr

Volltext

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer von Shaw, Alice T, Solomon, Benjamin J, Besse, Benjamin, Bauer, Todd M, Lin, Chia-Chi, Soo, Ross A, Riely, Gregory J, Ou, Sai-Hong Ignatius, Clancy, Jill S, Li, Sherry, Abbattista, Antonello, Thurm, Holger, Satouchi, Miyako, Camidge, D Ross, Kao, Steven, Chiari, Rita, Gadgeel, Shirish M, Felip, Enriqueta, Martini, Jean-François

Volltext

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study von Gainor, Justin F, Curigliano, Giuseppe, Kim, Dong-Wan, Lee, Dae Ho, Besse, Benjamin, Baik, Christina S, Doebele, Robert C, Cassier, Philippe A, Lopes, Gilberto, Tan, Daniel S W, Garralda, Elena, Paz-Ares, Luis G, Cho, Byoung Chul, Gadgeel, Shirish M, Thomas, Michael, Liu, Stephen V, Taylor, Matthew H, Mansfield, Aaron S, Zhu, Viola W, Clifford, Corinne, Zhang, Hui, Palmer, Michael, Green, Jennifer, Turner, Christopher D, Subbiah, Vivek

Volltext

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study von Langer, Corey J, Dr Prof, Gadgeel, Shirish M, Prof, Borghaei, Hossein, DO, Papadimitrakopoulou, Vassiliki A, Prof, Patnaik, Amita, MD, Powell, Steven F, MD, Gentzler, Ryan D, MD, Martins, Renato G, Prof, Stevenson, James P, MD, Jalal, Shadia I, MBBS, Panwalkar, Amit, MD, Yang, James Chih-Hsin, Prof, Gubens, Matthew, MD, Sequist, Lecia V, MD, Awad, Mark M, MD, Fiore, Joseph, PharmD, Ge, Yang, PhD, Raftopoulos, Harry, MD, Gandhi, Leena, Prof

Volltext

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK -rearranged non-small-cell lung cancer (AF-002JG): results... von Gadgeel, Shirish M, MD, Gandhi, Leena, MD, Riely, Gregory J, MD, Chiappori, Alberto A, MD, West, Howard L, MD, Azada, Michele C, MPH, Morcos, Peter N, PharmD, Lee, Ruey-Min, MD, Garcia, Linta, PharmD, Yu, Li, PhD, Boisserie, Frederic, MSc, Di Laurenzio, Laura, PhD, Golding, Sophie, MSc, Sato, Jotaro, MS, Yokoyama, Shumpei, MS, Tanaka, Tomohiro, MS, Ou, Sai-Hong Ignatius, Dr

Volltext

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial von Soria, Jean-Charles, Prof, Felip, Enriqueta, MD, Cobo, Manuel, MD, Lu, Shun, MD, Syrigos, Konstantinos, Prof, Lee, Ki Hyeong, MD, Göker, Erdem, MD, Georgoulias, Vassilis, Prof, Li, Wei, MD, Isla, Dolores, MD, Guclu, Salih Z, MD, Morabito, Alessandro, MD, Min, Young J, MD, Ardizzoni, Andrea, MD, Gadgeel, Shirish M, Prof, Wang, Bushi, PhD, Chand, Vikram K, MD, Goss, Glenwood D, Prof

Volltext

Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling von Qin, Angel, Johnson, Adrienne, Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj M., Schrock, Alexa B., Gadgeel, Shirish M.

Volltext

Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer von Gadgeel, Shirish M, Wozniak, Antoinette

Volltext

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study von Gadgeel, Shirish M., Stevenson, James P., Langer, Corey J., Gandhi, Leena, Borghaei, Hossein, Patnaik, Amita, Villaruz, Liza C., Gubens, Matthew, Hauke, Ralph, Yang, James Chih-Hsin, Sequist, Lecia V., Bachman, Robert, Saraf, Sanatan, Raftopoulos, Harry, Papadimitrakopoulou, Vassiliki

Volltext

Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs von Ahmad, Aamir, Maitah, Ma'in Y, Ginnebaugh, Kevin R, Li, Yiwei, Bao, Bin, Gadgeel, Shirish M, Sarkar, Fazlul H

Volltext

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort von Dziadziuszko, Rafal, Mok, Tony, Peters, Solange, Han, Ji-Youn, Alatorre-Alexander, Jorge, Leighl, Natasha, Sriuranpong, Virote, Pérol, Maurice, de Castro Junior, Gilberto, Nadal, Ernest, de Marinis, Filippo, Frontera, Osvaldo Arén, Tan, Daniel S.W., Lee, Dae Ho, Kim, Hye Ryun, Yan, Mark, Riehl, Todd, Schleifman, Erica, Paul, Sarah M., Mocci, Simonetta, Patel, Rajesh, Assaf, Zoe June, Shames, David S., Mathisen, Michael S., Gadgeel, Shirish M.

Volltext

Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer von Gadgeel, Shirish M

Volltext

Immune Checkpoint Inhibitors in the Management of Lung Cancer von Zimmermann, Stefan, Peters, Solange, Owinokoko, Taofeek, Gadgeel, Shirish M

Volltext

Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting von Gadgeel, Shirish M, Rai, Pragya, Annavarapu, Srinivas, Alam, Sartaj, Goldschmidt, Jerome H, West, Howard Jack, Santorelli, Melissa, Martins, Renata Eiras

Volltext

Targeted Therapy and Immune Therapy for Small Cell Lung Cancer von Gadgeel, Shirish M.

Volltext

Patient-Reported Outcomes in the Era of Immunotherapy Trials von Gadgeel, Shirish M.

Volltext

Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR von Gadgeel, Shirish M, Chen, Wei, Cote, Michele L, Bollig-Fischer, Aliccia, Land, Susan, Schwartz, Ann G, Bepler, Gerold

Volltext

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation von Jänne, Pasi A., Riely, Gregory J., Gadgeel, Shirish M., Heist, Rebecca S., Ou, Sai-Hong I., Pacheco, Jose M., Johnson, Melissa L., Sabari, Joshua K., Leventakos, Konstantinos, Yau, Edwin, Bazhenova, Lyudmila, Negrao, Marcelo V., Pennell, Nathan A., Zhang, Jun, Anderes, Kenna, Der-Torossian, Hirak, Kheoh, Thian, Velastegui, Karen, Yan, Xiaohong, Christensen, James G., Chao, Richard C., Spira, Alexander I.

Volltext

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR )-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epid... von Reckamp, Karen L, Frankel, Paul H, Ruel, Nora, Mack, Philip C, Gitlitz, Barbara J, Li, Tianhong, Koczywas, Marianna, Gadgeel, Shirish M, Cristea, Mihaela C, Belani, Chandra P, Newman, Edward M, Gandara, David R, Lara, Jr, Primo N

Volltext